Literature DB >> 6440959

Surgicel: its fate following implantation.

A M Pierce, O W Wiebkin, D F Wilson.   

Abstract

Surgicel, a local haemostatic gauze, is claimed to consist of oxidised regenerated cellulose. It is a polyanion, the functional unit of which is termed polyanhydroglucuronic acid. The ability of tissues to absorb Surgicel and its inherent haemostatic properties have been extensively investigated. This study was undertaken a) to determine the time required for absorption of Surgicel from implantation sites in the chest wall muscles of rats, and b) to establish mechanisms for its removal. Data derived from sequential uronic acid assays, histochemistry using the stain alcian blue, and transmission electron microscopy of implanted Surgicel were interpreted to reveal that Surgicel consists of at least two active components. These are a soluble uronic acid component which is lost after 6 h, and a fibrous component which persists. The latter material resembles Surgicel in the electron microscope and is still evident at the implantation site at 48 h post-implantation. Moreover, Surgicel can be characterized in vitro into at least two components according to its solubility under dissociative salt conditions (4M guanidinium chloride). A residual fibrous material could then be hydrolysed with 0.3N sodium hydroxide. We postulate that the absorption of the former salt soluble uronate in vivo is by early degradation and/or systemic clearance, whilst removal of the fibrous material requires phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440959     DOI: 10.1111/j.1600-0714.1984.tb01468.x

Source DB:  PubMed          Journal:  J Oral Pathol        ISSN: 0300-9777


  13 in total

Review 1.  Topical Collagen-Based Biomaterials for Chronic Wounds: Rationale and Clinical Application.

Authors:  Lisa J Gould
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-01-01       Impact factor: 4.730

Review 2.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

3.  Granuloma Due to Oxidized Regenerated Cellulose in an Aged Rhesus Macaque (Macaca mulatta).

Authors:  Marie-Josee Mf Lemoy; Angela Colagross Schouten; Don R Canfield
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

4.  Surgicel as an unusual cause of prolonged drainage.

Authors:  Vipul Gupta; Abdulnaser Al Said; Sunil Kumar; Ashhad A Khan
Journal:  J Surg Tech Case Rep       Date:  2010-07

5.  The pressures of surgicel(®) in cardiac surgery.

Authors:  Niket Dilip Arora; Roy Varghese; Sreeja Pavithran; Sivakumar Kothandam
Journal:  Ann Pediatr Cardiol       Date:  2015 May-Aug

6.  Comparison of regenerated and non-regenerated oxidized cellulose hemostatic agents.

Authors:  K M Lewis; D Spazierer; M D Urban; L Lin; H Redl; A Goppelt
Journal:  Eur Surg       Date:  2013-07-04       Impact factor: 0.953

7.  Oxidized (non)-regenerated cellulose affects fundamental cellular processes of wound healing.

Authors:  M U Wagenhäuser; J Mulorz; W Ibing; F Simon; J M Spin; H Schelzig; A Oberhuber
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

8.  An in vivo comparison of the efficacy of hemostatic powders, using two porcine bleeding models.

Authors:  Melinda H MacDonald; Allen Y Wang; Jeffrey W Clymer; Richard W Hutchinson; Richard Kocharian
Journal:  Med Devices (Auckl)       Date:  2017-11-30

9.  Effect of fibrin vs cellulose based haemostatic agents with traditional haemostatic procedures in thyroid surgery.

Authors:  Karanikolic Aleksandar; Djordjevic Miodagl; Djordjevic Nebojsa; Golubovic Ilija
Journal:  Pak J Med Sci       Date:  2017 Nov-Dec       Impact factor: 1.088

10.  Properties of collagen-based hemostatic patch compared to oxidized cellulose-based patch.

Authors:  Paul Slezak; Xavier Monforte; James Ferguson; Sanja Sutalo; Heinz Redl; Heinz Gulle; Daniel Spazierer
Journal:  J Mater Sci Mater Med       Date:  2018-05-23       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.